DNTH NASDAQ
Dianthus Therapeutics, Inc.
1W: +6.4%
1M: -10.4%
3M: -21.9%
YTD: +99.9%
1Y: +138.4%
3Y: +535.7%
5Y: -23.7%
$79.52
+0.19 (+0.24%)
After Hours: $80.54 (+1.02, +1.28%)
Weekly Expected Move ±5.4%
$69
$73
$77
$81
$85
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.44B.
Distance to default 14.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.5%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.44B.
Distance to default 14.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.5%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.4B
52W Range32.28-117.88
Volume748,687
Avg Volume961,567
Beta0.08
Dividend—
Analyst Ratings
Company Info
CEOMarino Garcia
Employees92
SectorHealthcare
IndustryBiotechnology
IPO Date2018-06-21
Websitedianthustx.com
7 Times Square
New York, NY 10036
US
New York, NY 10036
US
929-999-4055
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Latest News
451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A.
William Blair refreshes its analyst conviction list
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Legal & General Group Plc Buys New Shares in Dianthus Therapeutics, Inc. $DNTH
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CARR EDWARD | S-Sale | 7,928 | $100.43 | 2026-09-17 |
| CARR EDWARD | S-Sale | 6,771 | $101.37 | 2026-09-17 |
| CARR EDWARD | S-Sale | 3,501 | $102.39 | 2026-09-17 |
| CARR EDWARD | S-Sale | 1,100 | $103.20 | 2026-09-17 |
| CARR EDWARD | S-Sale | 700 | $104.39 | 2026-09-17 |